Live Chat Software
05 - 07 November, 2019 | Hilton London Olympia , London, United Kingdom

Content Library

Early and Managed Access Programmes | 2019 Agenda

Join the Early and Managed Access Programmes forum to explore topics in: Preparing for your Early Access Programmes with effective planning and a water-tight logistical strategy, navigating the complex and diverse regulatory and et ...

Featured Download

Trend & Investment Report: Early & Managed Access Programmes

The number of named patient requests has increased overtime due to patients, advocacy groups and physicians becoming increasingly well informed on the developmental pipelines of pharma and biotechs across the world. To keep up with rising demands, pharma companies have had to invest heavily in Ea ...

European Regulatory Handbook for Early & Managed Access Programmes

With regulations differing between European countries, it’s no easy feat launching an early access programme internationally! Ahead of the Early and Managed Access Programmes Forum taking place this November in London, Pharma IQ has gathered together key regulatory information you need a ...

Five Key Steps for Early Managed Access Programmes

Managing an Expanded Access Programme can bring many challenges for pharma companies, such as navigating the complex regulatory landscape, logistical planning, ethical concerns and unsolicited requests from increasingly well-informed patients. Pharma IQ spoke to Gregory Tuyteleers, Gl ...

Leveraging Real World Data From Early Access Programmes

One of the key benefits of Early Access Programmes is that they allow companies to collect real world data from patients within the programme, which can help inform a product’s effectiveness and value proposition. With insights from Tom Watson, Executive Vice President, Early Access Progra ...

Top 6 Factors To Consider In Your Forecasting Strategy

Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.

Five minutes with Vee Mapunde on: the growing influence of patient advocacy groups in Early Access Programmes

We had a chat with Vee Mapunde, Associate Consumer Lead at the National Cancer Research Institute (NCRI) on the role of patient advocacy groups in the Early Access Prorammes landscape, their missions and the tools they have to fulfill them, ahead of the Early and Managed Access Programmes confere ...

Three tips to ensure an ethical and sustainable Early Access Programme

Early and Managed Access Programmes can prolong the life of patients who have a life-threatening illness or a chronic or rare condition, by providing them access to investigational drugs. Their investigative nature does mean that ethical challenges often arise during their process. With this in m ...

Event Information

Sample Attendee List - Early & Managed Access Programmes 2019

Download the attendee list to see a sample of who you could meet at the Early & Managed Access Programmes Forum 2019!